Use of hormone replacement therapy (HRT) among women aged 45-64 years in the German EPIC-cohorts

Maturitas

Volumn 56, Issue 4, 2007, Pages 436-446

  Nagel, Gabriele ^a,b   Lahmann, Petra H ^c   Schulz, Mandy ^c   Boeing, Heiner ^c   Linseisen, Jakob ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

Author keywords

Correlates; EPIC Heidelberg; EPIC Potsdam; Hormone replacement therapy (HRT); Menopause; Prevalence

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; COHORT ANALYSIS; CORRELATION ANALYSIS; DIET; EDUCATION; ESTROGEN THERAPY; EUROPE; FEMALE; GERMANY; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OBESITY; OVARIECTOMY; PREVALENCE; REPRODUCTION; SMOKING;

ADULT; AGED; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; GERMANY; HUMANS; LOGISTIC MODELS; MIDDLE AGED; PATIENT COMPLIANCE; PREVALENCE; REPRODUCTION;

EID: 33947281056     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.11.008     Document Type: Article

References (43)

1. Krieger N., Lowy I., Aronowitz R., et al. Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol Community Health 59 9 (2005) 740-748
2. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., and Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85 2 (1995) 304-313
3. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350 9084 (1997) 1047-1059
5. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 9382 (2003) 419-427
6. Greiser C.M., Greiser E.M., and Doren M. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Hum Reprod Update 11 6 (2005) 561-573
7. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 14 (2004) 1701-1712
8. Ross R.K., Paganini-Hill A., Wan P.C., and Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92 4 (2000) 328-332
9. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 24 (2003) 3243-3253
10. Magnusson C., Baron J.A., Correia N., Bergstrom R., Adami H.O., and Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 81 3 (1999) 339-344
11. Mueller J.E., Doring A., Heier M., and Lowel H. Prevalence and determinants of hormone replacement therapy in German women 1984-1995. Maturitas 43 2 (2002) 95-104
12. Du Y., Melchert H.U., and Schafer-Korting M. Hormone replacement therapy in Germany: determinants and possible health-related outcomes. Results of National Health Surveys from 1984 to 1999. Maturitas 52 3-4 (2005) 223-234
13. Heitmann C., Greiser E., and Doren M. The impact of the Women's Health Initiative Randomized Controlled Trial 2002 on perceived risk communication and use of postmenopausal hormone therapy in Germany. Menopause 12 4 (2005) 405-411
14. Banks E., Barnes I., Baker K., and Key T.J. Use of hormonal therapy for menopause in nine European countries. IARC Sci Publ 156 (2002) 301-303
15. Boeing H., Wahrendorf J., and Becker N. EPIC-Germany-a source for studies into diet and risk of chronic diseases. European Investigation into Cancer and Nutrition. Ann Nutr Metab 43 4 (1999) 195-204
16. Riboli E., and Kaaks R. The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 26 Suppl 1 (1997) S6-S14
17. Boeing H., Korfmann A., and Bergmann M.M. Recruitment procedures of EPIC-Germany. European Investigation into Cancer and Nutrition. Ann Nutr Metab 43 4 (1999) 205-215
18. Manzoli L., Di Giovanni P., Del Duca L., et al. Use of hormone replacement therapy in Italian women aged 50-70 years. Maturitas 49 3 (2004) 241-251
19. Bakken K., Eggen A.E., and Lund E. Hormone replacement therapy in Norwegian women, 1996-1997. Maturitas 40 2 (2001) 131-141
20. Sargeant L.A., Wareham N.J., and Khaw K.T. Hormone replacement therapy and glucose tolerance in EPIC-Norfolk: a population-based study. Diabetes Metab Res Rev 16 1 (2000) 20-25
21. van Duijnhoven F.J., van Gils C.H., Bezemer I.D., Peeters P.H., van der Schouw Y.T., and Grobbee D.E. Use of hormones in the menopausal transition period in the Netherlands between 1993 and 1997. Maturitas 53 4 (2006) 462-475
22. Lundberg V., Tolonen H., Stegmayr B., Kuulasmaa K., and Asplund K. Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. Maturitas 48 1 (2004) 39-49
23. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 1 (2002) 49-57
24. Hulley S., Furberg C., Barrett-Connor E., et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 1 (2002) 58-66
25. Haas J.S., Kaplan C.P., Gerstenberger E.P., and Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140 3 (2004) 184-188
26. Clanget C., Hinke V., Lange S., Fricke R., Botko R., and Pfeilschifter J. Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. Changes after HERS II and WHI. Exp Clin Endocrinol Diabetes 113 9 (2005) 529-533
27. Löwel H. Hormontherapie - Sind Vergleiche zulässig?. Dtsch Aertzeblatt 100 40 (2003) B 2133-B 2134
28. Schwarz S., Volzke H., Alte D., Hoffmann W., John U., and Doren M. Gynaecological health care utilization and use of sex hormones-the study of Health in Pomerania. Hum Reprod 20 10 (2005) 2916-2922
29. Pesch B., Ko Y., Brauch H., et al. Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol 20 8 (2005) 699-711
30. Hoffmann M., Lindh-Astrand L., Ahlner J., Hammar M., and Kjellgren K.I. Hormone replacement therapy in the menopause. Structure and content of risk talk. Maturitas 50 1 (2005) 8-18
31. Olesen A.V., Johnsen S.P., Mortensen J.T., Boggild H., Olsen J., and Sorensen H.T. Socioeconomic status and use of postmenopausal hormone replacement therapy among Danish women. Acta Obstet Gynecol Scand 84 7 (2005) 639-644
32. Onland-Moret N.C., Peeters P.H., van der Schouw Y.T., Grobbee D.E., and van Gils C.H. Alcohol and endogenous sex steroid levels in postmenopausal women: a cross-sectional study. J Clin Endocrinol Metab 90 3 (2005) 1414-1419
33. Li C., Samsioe G., Lidfelt J., Nerbrand C., and Agardh C.D. Important factors for use of hormone replacement therapy: a population-based study of Swedish women. The Women's Health in Lund Area (WHILA) Study. Menopause 7 4 (2000) 273-281
34. Midgette A.S., and Baron J.A. Cigarette smoking and the risk of natural menopause. Epidemiology 1 6 (1990) 474-480
35. Nagel G., Altenburg H.P., Nieters A., Boffetta P., and Linseisen J. Reproductive and dietary determinants of the age at menopause in EPIC-Heidelberg. Maturitas 52 3-4 (2005) 337-347
36. MacMahon B., Trichopoulos D., Cole P., and Brown J. Cigarette smoking and urinary estrogens. N Engl J Med 307 17 (1982) 1062-1065
37. Carney P.A., Tosteson A.N., Titus-Ernstoff L., et al. Hormone therapies in women aged 40 and older: prevalence and correlates of use. Maturitas 53 1 (2006) 65-76
38. Hammar M., Brynhildsen J., Dabrosin L., et al. Hormone replacement therapy and previous use of oral contraceptives among Swedish women. Maturitas 25 3 (1996) 193-199
39. Rodstrom K., Bengtsson C., Lissner L., and Bjorkelund C. Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden. BMJ 319 7214 (1999) 890-893
40. Lawlor D.A., Davey S.G., and Ebrahim S. Commentary: the hormone replacement-coronary heart disease conundrum: is this the death of observational epidemiology?. Int J Epidemiol 33 3 (2004) 464-467
41. Persson I., Bergkvist L., Lindgren C., and Yuen J. Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: evidence of confounding by exposure characteristics. J Clin Epidemiol 50 5 (1997) 611-618
42. de Jong-van den Berg L.T., Faber A., and van den Berg P.B. HRT use in 2001 and 2004 in The Netherlands-a world of difference. Maturitas 54 2 (2006) 193-197
43. Mishra G., Kok H., Ecob R., Cooper R., Hardy R., and Kuh D. Cessation of hormone replacement therapy after reports of adverse findings from randomized controlled trials: evidence from a British Birth Cohort. Am J Public Health 96 7 (2006) 1219-1225